西格玛受体1在乳腺癌个性化治疗中的新兴作用
Taylor S Robinson1, Mahasin A Osman1
1Department of Medicine, Division of Oncology, College of Medicine and Life Sciences, University of Toledo, Toledo, OH 43614, USA.
Cancers
|July 14, 2023
概括
西格玛受体1 (SigmaR1) 是乳腺癌的潜在治疗点,特别是三阴性类型. 了解其作为寡合化适应器的作用可能会导致个性化医疗方法.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 细胞生物学 细胞生物学
背景情况:
- 乳腺癌复发和三阴性乳腺癌缺乏向治疗方法.
- 西格玛受体1 (SigmaR1) 与各种癌症和退行性疾病有关.
- 在癌症,特别是乳腺癌中,SigmaR1的精确机制尚不清楚,这阻碍了临床应用.
研究的目的:
- 审查Sigma受体1 (SigmaR1) 在乳腺癌中的作用.
- 讨论针对SigmaR1.1.的当前治疗策略.
- 为SigmaR1在疾病发病过程中的功能提出一个模型.
主要方法:
- 对SigmaR1在细胞通路中的功能进行文献综述.
- 对SigmaR1在癌症和退行性疾病中的参与进行分析.
- 探索SigmaR1作为治疗点的潜力.
主要成果:
- 西格玛R1定位在关键的细胞区域,如ER,MAM和核外.
- 西格玛R1影响关键的细胞功能,包括ER压力,信号和新陈代谢.
- 西格玛R1能够结合多种连接体的能力使其成为一个上下文依赖的治疗点.
结论:
- 西格玛R1不是一种型蛋白质,但可以作为一种寡合化适应器.
- 了解SigmaR1的适配器作用可以阐明它与各种疾病的关联.
- 这种理解可能有助于在个性化医学的SigmaR1向治疗的临床实用性.
相关概念视频
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
Transducer Mechanism: Enzyme-Linked Receptors
2.5K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.5K
Receptor Downregulation in MVBs
2.1K
Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
2.1K
Mitogens and the Cell Cycle
6.6K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.6K
G Protein-coupled Receptors
12.3K
G Protein-Coupled Receptors or GPCRs are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to sensory stimuli such as light, odors, hormones, cytokines, or neurotransmitters.
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
12.3K


